569 Targeting IL-15 delivery to PD-L1 expressing tumors with an Anti-PD-L1-IL-15 cytokine fusion IgM to enhance T Cell and NK Cell Mediated tumor cytotoxicity

Similar Items

• Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy
  by: Karin M. Knudson, et al.
  Published: (2019-03-01)
• Lung cancer cell-intrinsic IL-15 promotes cell migration and sensitizes murine lung tumors to anti-PD-L1 therapy
  by: Shaojie Hu, et al.
  Published: (2024-04-01)
• Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist
  by: Jeffrey Schlom, et al.
  Published: (2020-05-01)
• GDF15 Contributes to the Regulation of the Mechanosensitive Responses of PdL Fibroblasts through the Modulation of IL-37
  by: Julia Steinmetz, et al.
  Published: (2024-02-01)
• Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression
  by: Simon Gebremeskel, et al.
  Published: (2022-03-01)